ArticleMolecular systems biology2017
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.
Open access · goldAbstract read
In one paragraph
Article in Molecular systems biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 85 citations in OpenAlex.
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Aneuploidy promotes transient stress adaptation and metabolic flexibility in the human fungal pathogen Aspergillus fumigatus.Current biology : CB · 2026Article
- NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer.World journal of gastroenterology · 2025Article
- Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Metabolic adaptations in prostate cancer.British journal of cancer · 2024Review
- Patterns of Aneuploidy and Signaling Consequences in Cancer.Cancer research · 2024Review
- Ancestral aneuploidy and stable chromosomal duplication resulting in differential genome structure and gene expression control in trypanosomatid parasites.Genome research · 2024Article
- Evolutionary determinants of curability in cancer.Nature ecology & evolution · 2023Review
- Convergent TP53 loss and evolvability in cancer.BMC ecology and evolution · 2023Review
- GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.Journal of experimental & clinical cancer research : CR · 2023Article
- A fitness trade-off explains the early fate of yeast aneuploids with chromosome gains.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Unique Metabolic Contexts Sensitize Cancer Cells and Discriminate between Glycolytic Tumor Types.Cancers · 2023Article
- Chromosomal Instability, Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity.Cancers · 2022Review
- CONET: copy number event tree model of evolutionary tumor history for single-cell data.Genome biology · 2022Article
- Article
- Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness.Nature communications · 2022Article
- Tipping Cancer Cells Over the Edge: The Context-Dependent Cost of High Ploidy.Cancer research · 2022Article
- Article
- Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin.Cancer & metabolism · 2021Article
- Molecular characterization of ulcerative colitis-associated colorectal carcinomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 3 countries.
Nicholas A GrahamCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0002-6811-1941
Aspram MinasyanCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0002-0063-2513
Anastasia LomovaCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-4713-2089
Ashley CassCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Nikolas G BalanisCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Michael FriedmanCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Shawna ChanCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-0066-079X
Sophie ZhaoCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Adrian DelgadoCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
James GoCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Lillie BeckCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Christian HurtzDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0001-8346-190X
Carina NgDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Rong QiaoDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Johanna Ten HoeveCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Nicolaos PalaskasCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-0783-0683
Hong WuDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Markus MüschenDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Asha S MultaniDepartment of Genetics, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Elisa PortDepartment of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikolaus SchultzMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel BraasCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Heather R ChristofkDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Ingo K MellinghoffHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thomas G GraeberCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA, USA tgraeber@mednet.ucla.edu.ORCID 0000-0001-8574-9181
University of California, Los Angeles · USMemorial Sloan Kettering Cancer Center · USUniversity of California, San Francisco · USCalifornia NanoSystems Institute · USIcahn School of Medicine at Mount Sinai · USThe University of Texas MD Anderson Cancer Center · USUniversity of Southern California · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MUCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHUTE, JOHN P, MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6MVirology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CUMBERLAND, WILLIAM GLEN · 1991 to 2018
$39.9MTumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2000 to 2015
$29.9MTransductionally Redirected /Transcriptionally RestricteP50CA086306 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HERSCHMAN, HARVEY R. · 2000 to 2014
$29.0MMetabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DRY, SARAH M. · 2013 to 2017
$8.4MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MUCLA Scholars in Oncologic Molecular lmaging (SOMI)R25CA098010 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PHELPS, MICHAEL E · 2003 to 2013
$5.0MMolecular Mechanisms of IDH1-mediated GliomagenesisR01NS080944 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2012 to 2016
$2.0MCD25-mediated feedback control of BCR-signaling and its oncogenic mimicsR01CA213138 · NCI · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2017 to 2022
$1.9MNCATS NIH HHS UL1 TR000124NCI NIH HHS P01 CA168585NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA086306NCI NIH HHS P50 CA086438NCI NIH HHS R01 CA157644NCI NIH HHS R01 CA213138NCI NIH HHS R25 CA098010NCI NIH HHS R35 CA197628NIAID NIH HHS P30 AI028697NIAID NIH HHS U19 AI067769NINDS NIH HHS R01 NS080944
Abstract
Copy number alteration (CNA) profiling of human tumors has revealed recurrent patterns of DNA amplifications and deletions across diverse cancer types. These patterns are suggestive of conserved selection pressures during tumor evolution but cannot be fully explained by known oncogenes and tumor suppressor genes. Using a pan-cancer analysis of CNA data from patient tumors and experimental systems, here we show that principal component analysis-defined CNA signatures are predictive of glycolytic phenotypes, including
Indexed as
DNA Copy Number VariationsGlycolysisCell Line, TumorEvolution, MolecularGene AmplificationGene DeletionGene Expression ProfilingGene Expression Regulation, NeoplasticGenomic InstabilityHumansMetabolic Networks and PathwaysNeoplasmsPrincipal Component AnalysisSelection, GeneticaneuploidyDNA copy number alterationsgenomic instabilityglycolysismetabolism
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.